Cerebrospinal fluid biomarkers for brain tumor detection: clinical roles and current progress.
Liquid biopsy
biomarkers
brain tumor
cerebrospinal fluid
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
12
2019
accepted:
06
04
2020
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
2
5
2020
Statut:
epublish
Résumé
Brain tumors include those that originate within the brain (primary tumors) as well as those that arise from other cancers (metastatic tumors). The fragile nature of the brain poses a major challenge to access focal malignancies, which certainly limits both diagnostics and therapeutic approaches. This limitation has been alleviated with the advent of liquid biopsy technologies. Liquid biopsy represents a highly convenient, fast and non-invasive method, which allows multiple sampling and dynamic pathological detection. Biomarkers derived from liquid biopsies can promptly reflect changes on the gene expression profiling of tumors. Biomarkers derived from tumor cells contain abundant genetic information, which may provide a strong basis for the diagnosis and the individualized treatment of brain tumor patients. A series of body fluids can be assessed for liquid biopsy, including peripheral blood, cerebrospinal fluid (CSF), urine or saliva. Interestingly, the sensitivity and specificity of biomarkers from the CSF of patients with brain tumors is typically higher than those detected in the peripheral blood and other sources. Hence, here we describe and properly discuss the clinical roles of distinct classes of CSF biomarkers, isolated from patients with brain tumors, such as circulating tumor DNA (ctDNA), microRNA (miRNA), proteins, and extracellular vesicles (EVs).
Types de publication
Journal Article
Review
Langues
eng
Pagination
1379-1396Informations de copyright
AJTR Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
Acta Neuropathol Commun. 2019 Mar 18;7(1):43
pubmed: 30885253
Clin Chem Lab Med. 2018 May 24;56(6):869-879
pubmed: 29451858
Acta Neuropathol Commun. 2018 Aug 15;6(1):80
pubmed: 30111355
Neuropathol Appl Neurobiol. 2019 Dec;45(7):655-670
pubmed: 30977933
J Neurol Neurosurg Psychiatry. 1994 Oct;57(10):1212-5
pubmed: 7523604
Klin Onkol. 2019 Spring;32(3):181-186
pubmed: 31216849
Cancer. 1998 Mar 1;82(5):923-30
pubmed: 9486583
Cancers (Basel). 2019 Jul 05;11(7):
pubmed: 31284524
J Neurooncol. 2017 Oct;135(1):183-192
pubmed: 28730289
Am J Transl Res. 2019 Mar 15;11(3):1170-1183
pubmed: 30972154
Leuk Lymphoma. 2018 May;59(5):1256-1259
pubmed: 28849690
Neuro Oncol. 2019 Dec 17;21(12):1509-1518
pubmed: 31595305
Curr Treat Options Oncol. 2019 Nov 29;20(12):88
pubmed: 31784837
Nat Commun. 2015 Nov 10;6:8839
pubmed: 26554728
PLoS One. 2013 Oct 21;8(10):e78115
pubmed: 24205116
J Extracell Vesicles. 2017 May 24;6(1):1317577
pubmed: 28717417
Mol Diagn Ther. 2017 Oct;21(5):493-510
pubmed: 28477149
Neuropathol Appl Neurobiol. 2016 Apr;42(3):279-90
pubmed: 26111727
Biomed Pharmacother. 2019 Aug;116:108985
pubmed: 31146115
J Clin Oncol. 2014 Jul 1;32(19):2001-9
pubmed: 24733792
Handb Clin Neurol. 2017;146:139-169
pubmed: 29110768
Brain Tumor Pathol. 2019 Apr;36(2):29-39
pubmed: 30859343
Chin Med J (Engl). 2011 Jul;124(14):2222-7
pubmed: 21933631
J Neurooncol. 2012 Sep;109(2):239-44
pubmed: 22729947
Br J Haematol. 2018 Aug;182(3):384-403
pubmed: 29808930
Int J Mol Sci. 2019 Nov 14;20(22):
pubmed: 31739393
J Neurooncol. 2015 Jan;121(2):289-96
pubmed: 25391967
Curr Neurol Neurosci Rep. 2018 Mar 9;18(3):13
pubmed: 29520561
Mol Neurobiol. 2014 Oct;50(2):545-58
pubmed: 24696266
J Neurooncol. 2016 Aug;129(1):165-71
pubmed: 27294357
Neuro Oncol. 2017 Jun 1;19(6):833-844
pubmed: 27932423
ESMO Open. 2017 Oct 9;2(4):e000253
pubmed: 29067216
Curr Cancer Drug Targets. 2017;17(3):221-235
pubmed: 27528364
Neurosurgery. 2004 Sep;55(3):562-7; discussion 567-8
pubmed: 15335423
J Neuropathol Exp Neurol. 2018 Jul 1;77(7):628-635
pubmed: 29873738
J Mol Neurosci. 2012 Jun;47(2):243-8
pubmed: 22402993
J Invest Dermatol. 2001 Aug;117(2):375-8
pubmed: 11511319
Cancer Lett. 2018 Nov 1;436:10-21
pubmed: 30102952
J Neurooncol. 2014 Jun;118(2):225-238
pubmed: 24771250
J Extracell Vesicles. 2019 Jun 27;8(1):1627164
pubmed: 31275532
Dis Markers. 2018 Jan 17;2018:2908609
pubmed: 29581794
Clin Chem. 2015 Mar;61(3):514-22
pubmed: 25605683
Trends Mol Med. 2014 Aug;20(8):460-9
pubmed: 25027972
J Hematol Oncol. 2019 Oct 15;12(1):102
pubmed: 31615554
J Biol Chem. 2013 Feb 1;288(5):3097-111
pubmed: 23204518
Front Oncol. 2018 Sep 20;8:382
pubmed: 30294590
Hematol Oncol. 2018 Apr;36(2):429-435
pubmed: 29210102
J Oncol. 2019 Jun 9;2019:1639854
pubmed: 31281356
Curr Neurol Neurosci Rep. 2014 Sep;14(9):474
pubmed: 25037717
J Extracell Vesicles. 2019 Mar 21;8(1):1588555
pubmed: 30949309
Theranostics. 2019 Jul 9;9(18):5347-5358
pubmed: 31410219
BMC Cancer. 2019 Mar 1;19(1):192
pubmed: 30823914
Mol Ther Nucleic Acids. 2013 Jul 23;2:e109
pubmed: 23881452
Neurosurg Rev. 2014 Jul;37(3):367-80; discussion 380
pubmed: 24781189
Acta Neuropathol. 2019 Feb;137(2):297-306
pubmed: 30460397
Cancer Lett. 1998 Oct 23;132(1-2):181-6
pubmed: 10397472
Curr Neurol Neurosci Rep. 2016 Mar;16(3):25
pubmed: 26838352
J Magn Reson Imaging. 2018 May 7;:
pubmed: 29734497
Oncotarget. 2017 Jun 1;8(40):68769-68779
pubmed: 28978155
Proteomics. 2011 Mar;11(5):935-43
pubmed: 21271676
Neuro Oncol. 2012 Jun;14(6):689-700
pubmed: 22492962
Oncotarget. 2015 Sep 29;6(29):26971-81
pubmed: 26284486
Cancer Lett. 2017 Sep 28;404:62-69
pubmed: 28687355
J Clin Invest. 2019 Jan 2;129(1):137-149
pubmed: 30307407
J Clin Oncol. 2008 Jan 1;26(1):96-105
pubmed: 18056677
Ann Clin Transl Neurol. 2018 Oct 19;5(12):1611-1616
pubmed: 30564626
Cell Mol Neurobiol. 2016 Apr;36(3):353-60
pubmed: 26993514
Sci Technol Adv Mater. 2019 Jun 17;20(1):746-757
pubmed: 31447954
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Melanoma Res. 2014 Apr;24(2):120-30
pubmed: 24463459
Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9704-9
pubmed: 26195750
J Cancer. 2017 Oct 9;8(17):3631-3640
pubmed: 29151949
Case Rep Oncol. 2018 Feb 1;11(1):68-74
pubmed: 29515413
Target Oncol. 2019 Jun;14(3):343-350
pubmed: 31161597
J Mol Diagn. 2014 Sep;16(5):558-563
pubmed: 24994671
Blood. 2013 Jun 6;121(23):4740-8
pubmed: 23570798
Ir J Med Sci. 2018 Aug;187(3):767-775
pubmed: 29086194
Mol Cell Probes. 2019 Aug;46:101411
pubmed: 31173881
Mol Cancer. 2019 Mar 30;18(1):59
pubmed: 30925927
Nature. 2019 Jan;565(7741):654-658
pubmed: 30675060
Eur J Surg Oncol. 2010 Feb;36(2):201-7
pubmed: 19674866
Expert Rev Mol Diagn. 2015;15(10):1311-23
pubmed: 26394701
Adv Biol Regul. 2015 Jan;57:1-9
pubmed: 25294678
J Neurooncol. 2015 Jan;121(1):177-83
pubmed: 25258254
Mult Scler. 2018 Aug;24(9):1212-1223
pubmed: 28657431
Expert Rev Mol Diagn. 2014 May;14(4):439-52
pubmed: 24746164
Cancer Control. 2004 May-Jun;11(3):174-80
pubmed: 15153841
Chem Rev. 2018 Feb 28;118(4):1917-1950
pubmed: 29384376
Cells. 2019 Oct 02;8(10):
pubmed: 31581745
Noncoding RNA. 2018 Dec 25;5(1):
pubmed: 30585246
J Neurooncol. 2018 May;137(3):463-468
pubmed: 29327175
Acta Neuropathol Commun. 2017 Apr 17;5(1):28
pubmed: 28416018
J Exp Clin Cancer Res. 2019 May 29;38(1):231
pubmed: 31142339
Neurosurgery. 2014 Dec;75(6):N9-10
pubmed: 25406627
J Neurosurg. 2018 Aug;129(2):334-340
pubmed: 29053069
Neoplasma. 2003;50(5):377-9
pubmed: 14628092
Clin Lab. 2017 Oct 1;63(10):1717-1722
pubmed: 29035461
Neuro Oncol. 2012 Jan;14(1):29-33
pubmed: 21937590
Crit Rev Oncol Hematol. 2018 Jul;127:56-65
pubmed: 29891112
J Clin Oncol. 2016 Jul 10;34(20):2404-15
pubmed: 27161972
Neuro Oncol. 2015 Nov;17(11):1497-503
pubmed: 26014047
Acta Neurochir (Wien). 1986;83(3-4):144-50
pubmed: 3812039
Clin Cancer Res. 2018 Jun 15;24(12):2812-2819
pubmed: 29615461
Neuro Oncol. 2017 Nov 29;19(12):1618-1627
pubmed: 28521029
Oncotarget. 2015 Aug 28;6(25):20829-39
pubmed: 26246487
Neuro Oncol. 2017 Oct 19;19(11):1494-1502
pubmed: 28453784
J Clin Pathol. 2019 Apr;72(4):271-280
pubmed: 30467241